Pharmalot - The biotech won’t give up. Despite Lilly’s decision last week to abandon such a product, MannKind pledged to continue developing its insulin inhaler system even though its stock fell in reaction to Lilly’s announcement, The Los Angeles Times reports. But Hakan Edstrom, MannKind’s president, insists the stock, which has lost more than two-thirds of its value in the last year, will bounce back once investors realized its device is superior to the one Lilly had been pursuing....